Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AI Expert Exscientia Adds BMS To Big Pharma Client List

$50m Upfront, Potential Value Of Pact Is Over $1.2bn

Executive Summary

BMS is impressed with Exscientia's projects with recently acquired Celgene and has signed up to use the UK firm's artificial intelligence platform to accelerate the discovery of small molecules in areas including oncology and immunology.

You may also be interested in...



The Inexorable Rise Of Exscientia

The UK firm has not completed a clinical trial yet but having raised over $350m from its NASDAQ initial public offering and an extra $160m from a private placement, Exscientia's future looks extremely bright.

Digital Events, Social Media Move Up Pharma’s Marketing Playbook

Pharma is switching up its digital marketing playbook to map multiple touch points, including digital congresses and social media chats to deliver not just a product but a better customer experience, executives from Pfizer, Novo Nordisk and ViiV Healthcare say.

BMS Opts In On Exscientia’s AI-Designed Immune-Modulating Candidate

Bristol Myers Squibb will in-license an immune-modulating drug candidate created by AI-pioneer Exscientia, the first in their expanded multi-target alliance announced in May.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel